Physician profile
Veronica Takov
NPI 1316387533
$2,148.92
in general payments reported to CMS, 2019-2025
22 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $215 · 2021: $360 · 2022: $325 · 2023: $156 · 2024: $548 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $249.74 | 2021-2023 | Eliquis |
| Amgen INC. | $245.49 | 2019-2022 | |
| Abbvie INC. | $223.08 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $165.50 | 2024-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $157.14 | 2019-2024 | Airsupra |
| Genzyme Corporation | $146.82 | 2022-2025 | |
| Astellas Pharma US INC | $146.74 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $114.37 | 2019-2024 | Vaxelis, Gardasil 9, Gardasil |
| Novo Nordisk INC | $105.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $101.46 | 2020 | |
| Csl Behring | $99.47 | 2019 | |
| Exact Sciences Corporation | $72.50 | 2024-2025 | Cologuard Collection Kit |
| Organon LLC | $69.76 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.04 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $57.54 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.89 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $27.18 | 2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $15.09 | 2021 | |
| Glaxosmithkline, LLC. | $14.18 | 2024 | Bexsero, Shingrix, Arexvy |
| Therapeuticsmd, INC. | $12.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.42 | 2019 | |
| Pfizer INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Takov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.